Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Xx. m. x. x x. 46/2008 Sb. m. x. a xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 98/2013 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 11. xxxxxxxxx 2013 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Přílohy X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu ve xxxxxx.¹⁾

X xxxxx xxxxxx Xxxxxxx I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx a xxxxxxxxx xxxxxxxxx xxxxxxxx listinu x xxxxxxx xxxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X vstoupilo x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2014 x xxxxx xxxx xxxxxxxxx v xxxxxxxx i xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx přestalo xxxxxx xxxxx Přílohy I Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx xxxxxx od 1. xxxxx 2013 a xxxxxxxxx xxx č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx jazyka xx xxxxxxxxx současně.

¹⁾ Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxxx dne 19. xxxxx 2005 x Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX PROTI XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. ledna 2014

XXXXXX ZAKÁZANÝCH XXXXX X XXXXX DOPINGU XXX XXX 2014

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx od 1. ledna 2014

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx metod M1, X2 x X3.

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX SOUTĚŽI I XXXX SOUTĚŽ)

ZAKÁZANÉ XXXXX

X0. XXXXXXXXXXX LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx aktuálně schválena xxx humánní terapeutické xxxxxxx jakýmkoliv vládním xxxxxxxxxxxxx regulačním xxxxxx (xxxx. léčiva x xxxxxxxxxxxx nebo klinickém xxxxxx xxxxxxx nebo xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (XXX):

(x) Exogenní* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3x,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); fluoxymesteron; xxxxxxxxxx; furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17β-xx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; metandienon (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; norethandrolon; norklostebol; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4,:2,3]-5α-androstane); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); trenbolon (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxx** XXX, pokud xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), testosteron x xxxxxx xxxxxxxxxx x xxxxxxx, ale xx x xxxxxxxx xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx	5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
5α-androstan-3α,17β-diol	epi-dihydrotestosteron
5α-androstan-3β,17α-diol	epitestosteron
5α-androstan-3β,17β-diol	etiocholanolon
androst-4-en-3α,17α-diol	3α-hydroxy-5αandrostan-17-on
androst-4-en-3α,17β-diol	3β-hydroxy-5αandrostan-17-on
androst-5-en-3β,17α-diol	7α-hydroxy-DHEA
androst-5-en-3α,17α-diol	7β-hydroxy-DHEA
androst-5-en-3α,17β-dioI	7-keto-DHEA
androst-5-en-3β,17α-diol	19-norandrosteron
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx xxxxxxx xxxx sekce:

* "xxxxxxxx" xx vztahuje x xxxxx, xxxxxx xxxx xxxxxxxx přirozeně xxxxxxxxxxx.

** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM), tibolon, xxxxxxx, zilpaterol, ale xx s xxxxxxxx xxxxx xx xx.

X2. XXXXXXXXX HORMONY, RŮSTOVÉ XXXXXXX X XXXXXXXX XXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx podobnými biologickými xxxxxx xxxx zakázány:

1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (dEPO), stabilizátory xxxxxxx vyvolávajícího faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Xxxxxxxx/);

2. Xxxxxxxxxxxxxxxxxx (XX) a Xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx u xxxx;

3. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx;

4. Xxxxxxx xxxxxx (GH) a xxxx xxxxxxxxxx faktory x insulinu xxxxxxx xxxxxxx xxxxxx-1 (XXX-1).

Xxxxx xxxx jsou xxxxxxxx xxxxxxxxxxx xxxxxxx faktory:

Fibroblastové xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx růstový xxxxxx (XXX), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx odvozený z xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF), xxxxxx xxxx xxxxxxxxx jiné xxxxxxx faktory xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx xxxxx, šlach x xxxxxx, xxxxxx xxxxxxxx, využití energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx typy svalových xxxxxx;

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx, xxxxxx všech xxxxxxxxxx xxxxxxxxx xxxxxxx (např. x- a l-), xxxx zakázáni xxxxx xxxxxxxxxxx xxxxxxxxxxx (maximálně 1600 xxxxxxxxxx za 24 xxxxx), inhlalačního xxxxxxxxxxx (xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 hodin) x xxxxxxxxxxx, pokud xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči v xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx formoterolu x xxxx v koncentraci xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx výsledek xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx dávky nižší xxx xxxx xxxxxxx xxxxxxx.

X4. HORMONOVÉ X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx), xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, ale xx x omezením pouze xx xx.

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), zahrnující:

Raloxifen, xxxxxxxxx, xxxxxxxxx, xxx xx x omezením xxxxx xx xx.

3. Ostatní xxxxxxxxxxxxxx látky xxxxxxxxxx:

Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx x xxxxxxxx xxxxx na xx.

4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale ne x xxxxxxxx xxxxx xx ně.

5. Xxxxxxxxxxx xxxxxxxxxx:

x) Insuliny;

b) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x xxxxxxxxxxx s PPAR xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. AICAR)

S5. XXXXXXXXX X XXXXXXX XXXXXXXXX LÁTKY

Maskovací látky xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (xxxx. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, hydroxyethylškrobu x xxxxxxxxx), xxxxxxxxxx x další xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx zubní xxxxxxxx není xxxxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren, xxxxxxx (xxxx. xxxxxxxxx) a xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které nejsou xxxxxxxx).

Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx množství xxxxx se stanoveným xxxxxxxx limitem (xx. xxxxxxxxxx, xxxxxxxxxx, katin, xxxxxxx, metylefedrin a xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx nebo xxxxx maskovací látkou xx xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX METODY

M1. MANIPULACE X KRVÍ X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, alogenní (xxxxxxxxx) xxxx heterologní xxxx xxxx červených krvinek x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.

2. Xxxxx zvyšování spotřeby, xxxxxxx xxxx dodávky xxxxxxx, zahrnující modifikované xxxxxxxxxxxxx xxxxxxxx (např. xxxxxx xxxxxxxx založené xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx s xxxxxxxx xxxxx na ně. Xxxxxxxxxxxx xxxxxxxx zakázána xxxx.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx manipulace x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x platnost Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx zahrnuje xxxxxx a/nebo xxxxxx (xxxx. proteázami) xxxx, xxx xx s xxxxxxxx xxxxx xx xx.

2. Nitrožilní xxxxxx x/xxxx xxxxxxx xxxx xxx 50 ml xx 6 hodin xxxxx infuzí legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.

X3. XXXXXX DOPING

Z xxxxxx xxxxxxxxxx ke zvýšení xxxxxxxxxxx xxxxxx je xxxxxxxx následující:

1. Xxxxxxxx xxxxxxxx nukleových xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

XXXXX X XXXXXX XXXXXXXX XXX SOUTĚŽI

Kromě xxxxxxxxx X0 xx X5 x X1 xx X3 xxxxxxxxx výše xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. STIMULANCIA

Všechna xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (např. d- x x-) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx imidazoiu x xxxxxxx xxxxxx xxxxxxxx xxxxxxx x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx rok 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Nespecifická xxxxxxxxxxx:

Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, amifenazol, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, fendimetrazin, xxxxxxxxx, fenfluramin, xxxxxxxx, xxxxxxxxxxx, fenproporex, fentermin, xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/, xxxxxxxxxx, xxxxxxxxxxx, kokain, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, metamfetamin (x-), xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.

Stimulancium, xxxxx xxxx výslovně xxxxxxx x xxxxx xxxxxxxx, je Specifickou xxxxxx.

(x) Xxxxxxxxxx stimulancia (xxxxxxxx):

Xxxxxxxxx (xxxxxxxxx)****, xxxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx***, xxxxxxxx, xxxxxxxxxxxxx, etylefrin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxx (parahydroamfetamin), xxxxxxxxxxxx, xxxxx**, xxxxxxx x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx***, xxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), níketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxx), xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, tuaminoheptan x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2014 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx xx zakázaný xxxxx při koncentraci xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx x methylefedrin jsou xxxxxxxx při xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxx xxxxxx adrenalinu (xxxxxxxxxx) (xxxx. nosní, xxxx xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx není xxxxxxxx.

***** Xxxxxxxxxxxxx xx xxxxxxx, pokud xxxx xxxxxxxxxxx x xxxx xx vyšší xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. NARKOTIKA

Zakázané je xxxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, petidin.

S8. KANABINOIDY

Přírodní (xxxx. xxxxx, xxxxxx x xxxxxxxxx) nebo xxxxxxxxxx delta9-tetrahydrokanabinol (THC) x xxxxxxxxxxxxxx (xxxx. "Xxxxx", XXX018, XXX073 x XX-210) jsou xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, rektálně, xxxxxxxxxx nebo nitrosvalovou xxxxxxxx jsou zakázané.

LÁTKY XXXXXXXX X XXXXXXXX XXXXXXXX

X1. XXXXXXX

Xxxxxxx (etanol) xx zakázaný xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx provádět xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Prahová xxxxxxx pro xxxxxxxx xxxxxxxxxxx pravidla xx xxxxxxxxxxxx xxxxxxxxxxx alkoholu x xxxx 0.10 x/x.

• Xxxxxxxxxxxx sport (XXX)

• Karate (XXX)

• Xxxxxxx sporty x xxxxxxxxxxxx (FAI)

• Xxxxxxxxxxx (XX)

• Motocyklový xxxxx (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx pouze Xxx Soutěži v xxxxxxxxxxxxx xxxxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)

• Xxxx (XXX)

• Lukostřelba (XX) (xxxxxxxx také Xxxx xxxxxx)

• Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxx (ISSF, XXX) (zakázané také Xxxx xxxxxx)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, esmolol, karteolol, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, nadolol, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

Informace

Právní předpis x. 47/2014 Xx. x. x. xxxxx xxxxxxxxx xxxx 20.9.2014.

Právní xxxxxxx x. 47/2014 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 19/2017 Sb. m. s. s xxxxxxxxx xx 6.4.2017.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není aktualizováno, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.